<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628103</url>
  </required_header>
  <id_info>
    <org_study_id>SEP361-308</org_study_id>
    <nct_id>NCT05628103</nct_id>
  </id_info>
  <brief_title>A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication</brief_title>
  <official_title>An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study that will evalute how well SEP-363856 works and how safe it is in people&#xD;
      with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.&#xD;
      This study will accept both male and female participants, ages of 18 years to 65 years, with&#xD;
      schizophrenia. The study will take place in approxmiately 24 study sites in North America.&#xD;
      Particpants should expect to be in the study for up to 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an 8-week, outpatient, multicenter, open-label, single-group, flexible-dose study&#xD;
      designed to evaluate the safety and tolerability, as well as effectiveness of switching&#xD;
      clinically stable adult subjects with schizophrenia from a typical or atypical antipsychotic&#xD;
      to SEP-363856. This study is projected to enroll approximately 120 subjects into a single&#xD;
      treatment group (SEP-363856).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2022</start_date>
  <completion_date type="Anticipated">July 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who discontinue for clinical reasons (ie, discontinued due to an adverse event [AE] or lack of efficacy)</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who discontinue for any reason (ie, all causes for discontinuation)</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP-363856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP-363856 flexibly dosed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856</intervention_name>
    <description>SEP-363856 flexibly dosed</description>
    <arm_group_label>SEP-363856</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: This list is not all inclusive&#xD;
&#xD;
          -  Male or female subject between 18 to 65 years of age.&#xD;
&#xD;
          -  Subject meets DSM-5 criteria for a diagnosis of schizophrenia.&#xD;
&#xD;
          -  Subject is judged to be clinically stable (ie, no evidence of an acute exacerbation of&#xD;
             schizophrenia) by the Investigator for at least 8 weeks prior to Baseline.&#xD;
&#xD;
          -  Subject must be judged by the Investigator to be an appropriate candidate for&#xD;
             switching current antipsychotic medication due to safety or tolerability concerns&#xD;
             and/or insufficient efficacy.&#xD;
&#xD;
          -  Subject is taking an oral antipsychotic and the antipsychotic regimen has been stable&#xD;
             for at least 6 weeks prior to Screening.&#xD;
&#xD;
        Exclusion Criteria:This list is not all inclusive&#xD;
&#xD;
          -  Subject has a current DSM-5 diagnosis or presence of symptoms consistent with a major&#xD;
             psychiatric disorder, other than schizophrenia, that is the primary focus of&#xD;
             treatment.&#xD;
&#xD;
          -  Subject is at significant risk of harming self or others based on investigator's&#xD;
             judgment.&#xD;
&#xD;
          -  Subject has any clinically significant unstable medical condition or any clinically&#xD;
             significant chronic disease that in the opinion of the Investigator, would limit the&#xD;
             subject's ability to complete and/or participate in the study.&#xD;
&#xD;
          -  Female subject who is pregnant or lactating.&#xD;
&#xD;
          -  Subject tests positive for drugs of abuse at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CNS Medical Director</last_name>
    <phone>1-866-503-6351</phone>
    <email>ClinicalTrialDisclosure@sunovion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Research Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Austina Cho, MD</last_name>
      <phone>714-999-6688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Bussel</last_name>
      <phone>424-227-8127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research, LLC</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling</last_name>
      <phone>714-799-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Bari</last_name>
      <phone>619-303-6130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Innovations, Inc</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald A Maguire, MD</last_name>
      <phone>951-300-4924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Benbow, MD</last_name>
      <phone>619-481-5252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CMB Clinical Trials</name>
      <address>
        <city>Santee</city>
        <state>California</state>
        <zip>92071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yashwant S Chaudhri</last_name>
      <phone>909-423-0367</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cenexel CNS Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Shirikjian, DO</last_name>
      <phone>310-523-4200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Larkin Behavioral Health Services</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Treese, MD</last_name>
      <phone>305-722-8444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research, Inc</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Lapeyra, MD</last_name>
      <phone>305-722-8444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emelina Arocha, MD</last_name>
      <phone>305-392-0279</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Psychiatry, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Medina, MD</last_name>
      <phone>407-718-3530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Discovery Research LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Purselle</last_name>
      <phone>470-777-8839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Johnson, MD</last_name>
      <phone>404-881-5800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Behavioral Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30358</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneel Katragadda, MD</last_name>
      <phone>770-458-0447</phone>
      <phone_ext>op 3</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uptown Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sonnenberg, PhD</last_name>
      <phone>773-989-8313</phone>
      <phone_ext>119</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CBH Health</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elia Acevedo Diaz, MD</last_name>
      <phone>301-251-4702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohd Malik, MD</last_name>
      <phone>314-849-1853</phone>
      <phone_ext>206</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Blanchard</last_name>
      <phone>856-753-7335</phone>
      <phone_ext>722</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hope Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurian Abraham, MD</last_name>
      <phone>980-209-9784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Barker, MD</last_name>
      <phone>828-322-3222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charak Clinical Research Center</name>
      <address>
        <city>Garfield Heights</city>
        <state>Ohio</state>
        <zip>44125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Ranjan, MD</last_name>
      <phone>877-463-9633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Bartley, MD</last_name>
      <phone>214-396-4844</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>April 25, 2023</last_update_submitted>
  <last_update_submitted_qc>April 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study may be made available upon request via the Vivli Center for Global Clinical Research Data site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available upon request within 12 months of posting the study results on ct.gov.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://Vivli.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

